Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) EBIT (2020 - 2025)

Cytek Biosciences' EBIT history spans 6 years, with the latest figure at -$5.6 million for Q4 2025.

  • For Q4 2025, EBIT fell 287.34% year-over-year to -$5.6 million; the TTM value through Dec 2025 reached -$40.4 million, down 96.78%, while the annual FY2025 figure was -$40.4 million, 96.77% down from the prior year.
  • EBIT reached -$5.6 million in Q4 2025 per CTKB's latest filing, up from -$9.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $3.8 million in Q2 2021 to a low of -$15.0 million in Q1 2025.
  • Average EBIT over 5 years is -$4.1 million, with a median of -$3.3 million recorded in 2022.
  • Peak YoY movement for EBIT: plummeted 924.35% in 2023, then soared 2279.56% in 2024.
  • A 5-year view of EBIT shows it stood at $1.3 million in 2021, then tumbled by 93.62% to $84000.0 in 2022, then crashed by 263.1% to -$137000.0 in 2023, then skyrocketed by 2279.56% to $3.0 million in 2024, then plummeted by 287.34% to -$5.6 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's EBIT are -$5.6 million (Q4 2025), -$9.2 million (Q3 2025), and -$10.6 million (Q2 2025).